Payment overview · 2025
General Payments
$2,111.27
119 reported records · 32 companies
Healthcare provider profile · identity verified
Imran Haque, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HIGH POINT, NC · NPI 1134107022
Verified facts
What the public records show
CMS Open Payments records show Imran Haque, M.D. received $2,111.27 in general payments during 2025 across 119 reported records.
ABBVIE INC. accounted for 12.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1524 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.97 | 12.1% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.44 | 10.5% | 14 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $154.80 | 7.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $153.04 | 7.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $132.30 | 6.3% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.74 | 5.8% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $86.85 | 4.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $79.09 | 3.8% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $75.71 | 3.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.95 | 3.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.26 | 3.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $60.32 | 2.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $59.24 | 2.8% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $58.61 | 2.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.43 | 2.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.20 | 2.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.05 | 2.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.19 | 2.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.87 | 1.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.85 | 1.8% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $28.30 | 1.3% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $25.09 | 1.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.94 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.48 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.53 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.03 | 0.9% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $18.88 | 0.9% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.9% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.02 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.72 | 0.7% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.67 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,068.77 | 118 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $195.24 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $164.53 | 15 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $154.80 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $153.04 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.77 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $129.82 | 13 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $121.74 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.11 | 6 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $86.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.37 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $79.09 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $75.71 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $72.67 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.08 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.60 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $60.32 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $59.24 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $58.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.43 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.20 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.05 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.69 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.84 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| Crysvita Normalized: crysvita |
Drug | Ultragenyx Pharmaceutical Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.07 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1524 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 169 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 203 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 220 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
184 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
169 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
35 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
220 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
208 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
203 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
319 | 45 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
195 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | 11 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1524 | 170 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
93 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2890 | 478 |
| Gabapentin | Gabapentin | 1690 | 307 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1560 | 278 |
| Eliquis | Apixaban | 1524 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 1475 | 275 |
| Trazodone Hcl | Trazodone Hcl | 1289 | 232 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1226 | 223 |
| Omeprazole | Omeprazole | 1153 | 251 |
| Furosemide | Furosemide | 1121 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 974 | 210 |
| Metformin Hcl | Metformin Hcl | 970 | 169 |
| Tamsulosin Hcl | Tamsulosin Hcl | 953 | 160 |
| Potassium Chloride | Potassium Chloride | 906 | 164 |
| Lisinopril | Lisinopril | 902 | 179 |
| Oxycodone Hcl | Oxycodone Hcl | 867 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 761 | 145 |
| Sertraline Hcl | Sertraline Hcl | 760 | 128 |
| Famotidine | Famotidine | 694 | 119 |
| Donepezil Hcl | Donepezil Hcl | 667 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 667 | 118 |
| Mirtazapine | Mirtazapine | 659 | 124 |
| Carvedilol | Carvedilol | 623 | 124 |
| Clopidogrel | Clopidogrel Bisulfate | 588 | 112 |
| Losartan Potassium | Losartan Potassium | 585 | 123 |
| Levetiracetam | Levetiracetam | 574 | 89 |
| Alprazolam | Alprazolam | 538 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 517 | 102 |
| Montelukast Sodium | Montelukast Sodium | 489 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 478 | 83 |
| Quetiapine Fumarate | Quetiapine Fumarate | 469 | 89 |
| Divalproex Sodium | Divalproex Sodium | 467 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 424 | 140 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 421 | 85 |
| Fluticasone Propionate | Fluticasone Propionate | 396 | 115 |
| Memantine Hcl | Memantine Hcl | 395 | 72 |
| Risperidone | Risperidone | 373 | 52 |
| Xarelto | Rivaroxaban | 368 | 38 |
| Olanzapine | Olanzapine | 354 | 62 |
| Buspirone Hcl | Buspirone Hcl | 350 | 69 |
| Humalog Kwikpen U-100 | Insulin Lispro | 349 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 347 | 66 |
| Januvia | Sitagliptin Phosphate | 336 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 334 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 325 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 325 | 38 |
| Meloxicam | Meloxicam | 323 | 65 |
| Trulicity | Dulaglutide | 319 | 45 |
| Latanoprost | Latanoprost | 313 | 65 |
| Ondansetron Hcl | Ondansetron Hcl | 304 | 171 |
| Baclofen | Baclofen | 302 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 293 | 64 |
| Allopurinol | Allopurinol | 285 | 58 |
| Finasteride | Finasteride | 273 | 54 |
| Novolog Flexpen | Insulin Aspart | 273 | 46 |
| Simvastatin | Simvastatin | 273 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 258 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 247 | 48 |
| Alendronate Sodium | Alendronate Sodium | 245 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 244 | 48 |
| Aripiprazole | Aripiprazole | 243 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 243 | 37 |
| Prednisone | Prednisone | 242 | 107 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 238 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 232 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 220 | 41 |
| Lamotrigine | Lamotrigine | 215 | 34 |
| Ezetimibe | Ezetimibe | 212 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 212 | 32 |
| Jardiance | Empagliflozin | 208 | 33 |
| Mounjaro | Tirzepatide | 203 | 37 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 202 | 47 |
| Spironolactone | Spironolactone | 199 | 42 |
| Clonazepam | Clonazepam | 195 | 29 |
| Entresto | Sacubitril/Valsartan | 195 | 27 |
| Nystatin | Nystatin | 194 | 93 |
| Midodrine Hcl | Midodrine Hcl | 189 | 39 |
| Atenolol | Atenolol | 186 | 34 |
| Ozempic | Semaglutide | 186 | 36 |
| Linzess | Linaclotide | 184 | 49 |
| Azithromycin | Azithromycin | 181 | 126 |
| Topiramate | Topiramate | 179 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 173 | 25 |
| Pregabalin | Pregabalin | 173 | 38 |
| Ibuprofen | Ibuprofen | 172 | 59 |
| Farxiga | Dapagliflozin Propanediol | 169 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 167 | 21 |
| Sevelamer Carbonate | Sevelamer Carbonate | 164 | 37 |
| Torsemide | Torsemide | 162 | 38 |
| Myrbetriq | Mirabegron | 161 | 23 |
| Divalproex Sodium Er | Divalproex Sodium | 160 | 25 |
| Lactulose | Lactulose | 159 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 29 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 156 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 156 | 34 |
| Lorazepam | Lorazepam | 155 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 24 |
| Oxcarbazepine | Oxcarbazepine | 148 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 147 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 146 | 67 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 145 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 142 | 32 |
| Tramadol Hcl | Tramadol Hcl | 140 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 138 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 129 | 23 |
| Clozapine | Clozapine | 129 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 127 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 127 | 24 |
| Celecoxib | Celecoxib | 126 | 32 |
| Fenofibrate | Fenofibrate | 123 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 122 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 120 | 25 |
| Cephalexin | Cephalexin | 118 | 84 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 117 | 85 |
| Fluconazole | Fluconazole | 117 | 56 |
| Propranolol Hcl | Propranolol Hcl | 117 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 116 | 25 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 115 | 43 |
| Methocarbamol | Methocarbamol | 112 | 26 |
| Promethazine Hcl | Promethazine Hcl | 108 | 36 |
| Bupropion Xl | Bupropion Hcl | 107 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 78 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 107 | 27 |
| Clonidine Hcl | Clonidine Hcl | 106 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 20 |
| Metformin Hcl Er | Metformin Hcl | 104 | 19 |
| Sucralfate | Sucralfate | 103 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 57 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 97 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 97 | 39 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 95 | 18 |
| Rexulti | Brexpiprazole | 95 | 11 |
| Levofloxacin | Levofloxacin | 93 | 74 |
| Xifaxan | Rifaximin | 93 | suppressed |
| Glipizide Er | Glipizide | 90 | 16 |
| Valacyclovir | Valacyclovir Hcl | 90 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 90 | 38 |
| Ketoconazole | Ketoconazole | 89 | 35 |
| Haloperidol | Haloperidol | 88 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | 19 |
| Glipizide | Glipizide | 86 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 59 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 85 | 20 |
| Lidocaine | Lidocaine | 84 | 20 |
| Tradjenta | Linagliptin | 84 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 84 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 25 |
| Budesonide | Budesonide | 80 | 21 |
| Digoxin | Digoxin | 80 | 15 |
| Lubiprostone | Lubiprostone | 80 | 13 |
| Diazepam | Diazepam | 79 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 78 | 17 |
| Permethrin | Permethrin | 78 | 42 |
| Amantadine | Amantadine Hcl | 77 | 14 |
| Nifedipine Er | Nifedipine | 76 | 12 |
| Ondansetron Odt | Ondansetron | 75 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 56 |
| Tresiba Flextouch U-100 | Insulin Degludec | 73 | 19 |
| Erythromycin | Erythromycin Base | 70 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 14 |
| Nitroglycerin | Nitroglycerin | 68 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 66 | 16 |
| Meclizine Hcl | Meclizine Hcl | 66 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 66 | 18 |
| Carbamazepine | Carbamazepine | 65 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 65 | 12 |
| Ingrezza | Valbenazine Tosylate | 64 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 62 | 24 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 61 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 60 | 20 |
| Risperidone Odt | Risperidone | 60 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 59 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 56 | suppressed |
| Ofloxacin | Ofloxacin | 55 | 27 |
| Sodium Chloride | 0.9 % Sodium Chloride | 55 | 19 |
| Chlorthalidone | Chlorthalidone | 53 | suppressed |
| Colchicine | Colchicine | 53 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 52 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 50 | suppressed |
| Calcitriol | Calcitriol | 50 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 50 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | suppressed |
| Carbamazepine Er | Carbamazepine | 49 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 49 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 49 | 13 |
| Metronidazole | Metronidazole | 49 | 26 |
| Vascepa | Icosapent Ethyl | 49 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 47 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 47 | 28 |
| Scopolamine | Scopolamine | 47 | suppressed |
| Timolol Maleate | Timolol Maleate | 46 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 46 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 44 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 44 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 44 | 16 |
| Amoxicillin | Amoxicillin | 43 | 32 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 12 |
| Mupirocin | Mupirocin | 43 | 22 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 43 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 42 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 42 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Olanzapine Odt | Olanzapine | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 11 |
| Creon | Lipase/Protease/Amylase | 40 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Roflumilast | Roflumilast | 40 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 40 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Methimazole | Methimazole | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 36 | 20 |
| Paliperidone Er | Paliperidone | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | 13 |
| Estradiol | Estradiol | 35 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 35 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Ibu | Ibuprofen | 33 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 33 | 32 |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 13 |
| Hydrocortisone | Hydrocortisone | 31 | 17 |
| Levemir Flexpen | Insulin Detemir | 31 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 13 |
| Febuxostat | Febuxostat | 29 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Ubrelvy | Ubrogepant | 28 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Kerendia | Finerenone | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 25 | 12 |
| Loxapine | Loxapine Succinate | 25 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 17 |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | 12 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Nadolol | Nadolol | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 22 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Nystop | Nystatin | 21 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 20 | 11 |
| Propylthiouracil | Propylthiouracil | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Eplerenone | Eplerenone | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Dayvigo | Lemborexant | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Edurant | Rilpivirine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Clomid | Clomiphene Citrate | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Relafen Ds | Nabumetone | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Perphenazine | Perphenazine | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,111.27 · 119 records | ABBVIE INC. | ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, BOTOX, BREZTRI, CAPLYTA, Crysvita, ELIQUIS, EPIDIOLEX, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, IBSRELA, INCEPTIV, INTELLIS ADAPTIVESTIM, JATENZO, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, Nimbl, Ohtuvayre, Ozempic, QULIPTA, RELISTOR, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, Tlando, UBRELVY, ULTOMIRIS, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error